Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment.
Koulouridi A, Messaritakis I, Theodorakis E, Chondrozoumaki M, Sfakianaki M, Gouvas N, Tsiaoussis J, Mavroudis D, Tzardi M, Souglakos J. Koulouridi A, et al. Among authors: messaritakis i. Cancers (Basel). 2021 Jul 15;13(14):3552. doi: 10.3390/cancers13143552. Cancers (Basel). 2021. PMID: 34298766 Free PMC article.
Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer.
Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, Mavroudis D, Georgoulias V, Souglakos J. Vardakis N, et al. Among authors: messaritakis i. Clin Cancer Res. 2011 Jan 1;17(1):165-73. doi: 10.1158/1078-0432.CCR-10-0565. Epub 2010 Nov 11. Clin Cancer Res. 2011. PMID: 21071514
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.
Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. Saridaki Z, et al. Among authors: messaritakis i. PLoS One. 2011 Jan 20;6(1):e15980. doi: 10.1371/journal.pone.0015980. PLoS One. 2011. PMID: 21283802 Free PMC article.
BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome.
Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. Saridaki Z, et al. Among authors: messaritakis i. PLoS One. 2013 Dec 18;8(12):e84604. doi: 10.1371/journal.pone.0084604. eCollection 2013. PLoS One. 2013. PMID: 24367680 Free PMC article.
Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer.
Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Alam S, Lagoudaki ED, Messaritakis I, Zoras O, Mavroudis D, Georgoulias V, Souglakos J. Sfakianaki M, et al. Among authors: messaritakis i. Cancer Res Treat. 2019 Oct;51(4):1518-1526. doi: 10.4143/crt.2019.008. Epub 2019 Mar 20. Cancer Res Treat. 2019. PMID: 30913862 Free PMC article.
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.
Matikas A, Souglakos J, Katsaounis P, Kotsakis A, Kouroupakis P, Pantazopoulos N, Kentepozidis N, Nikolaidi A, Messaritakis I, Tzovara I, Hatzidaki D, Prinarakis E, Georgoulias V. Matikas A, et al. Among authors: messaritakis i. Target Oncol. 2019 Jun;14(3):285-293. doi: 10.1007/s11523-019-00647-3. Target Oncol. 2019. PMID: 31203498 Clinical Trial.
58 results